{"id":257161,"date":"2025-12-13T18:38:36","date_gmt":"2025-12-13T17:38:36","guid":{"rendered":"https:\/\/r3i.org\/editorials-10-25-%e3%83%aa%e3%83%9d%e3%82%bf%e3%83%b3%e3%83%91%e3%82%afa%e3%81%af%e6%ae%8b%e5%ad%98%e5%bf%83%e8%a1%80%e7%ae%a1%e3%83%aa%e3%82%b9%e3%82%af%e5%9b%a0%e5%ad%90%ef%bc%9a%e5%90%8c\/"},"modified":"2026-03-05T17:56:19","modified_gmt":"2026-03-05T16:56:19","slug":"editorials-10-25-%e3%83%aa%e3%83%9d%e3%82%bf%e3%83%b3%e3%83%91%e3%82%afa%e3%81%af%e6%ae%8b%e5%ad%98%e5%bf%83%e8%a1%80%e7%ae%a1%e3%83%aa%e3%82%b9%e3%82%af%e5%9b%a0%e5%ad%90%ef%bc%9a%e5%90%8c","status":"publish","type":"page","link":"https:\/\/r3i.org\/ja\/editorials-10-25-%e3%83%aa%e3%83%9d%e3%82%bf%e3%83%b3%e3%83%91%e3%82%afa%e3%81%af%e6%ae%8b%e5%ad%98%e5%bf%83%e8%a1%80%e7%ae%a1%e3%83%aa%e3%82%b9%e3%82%af%e5%9b%a0%e5%ad%90%ef%bc%9a%e5%90%8c\/","title":{"rendered":"Editorials 10\/25 – \u30ea\u30dd\u30bf\u30f3\u30d1\u30af(a)\u306f\u6b8b\u5b58\u5fc3\u8840\u7ba1\u30ea\u30b9\u30af\u56e0\u5b50\uff1a\u540c\u5b9a\u3068\u7ba1\u7406"},"content":{"rendered":"

[et_pb_section fb_built=”1″ admin_label=”Header” _builder_version=”4.27.4″ _module_preset=”35f37621-1062-4ae6-955d-76a3167a2aa8″ background_image=”https:\/\/r3i.org\/wp-content\/uploads\/2024\/12\/pexels-pixabay-267582.jpg&#8221<\/a>; parallax=”on” min_height=”280.8px” min_height_tablet=”367px” min_height_phone=”262.4px” min_height_last_edited=”on|phone” height=”289px” height_tablet=”289px” height_phone=”159px” height_last_edited=”on|phone” custom_margin_tablet=”” custom_margin_phone=”-17px||||false|false” custom_margin_last_edited=”on|phone” custom_padding=”0vw||0vw||true|false” collapsed=”on” global_colors_info=”{%22gcid-primary-color%22:%91%22quote_text_color%22,%22background_color_gradient_stops%22%93}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_text_color=”#FFFFFF” header_2_text_color=”#FFFFFF” custom_padding=”1px|||||” global_colors_info=”{}”]<\/p>\n

R3i\u793e\u8aac<\/h2>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_text_color=”#FFFFFF” custom_margin=”-22px|||||” custom_margin_tablet=”-22px|||||” custom_margin_phone=”-35px||||false|false” custom_margin_last_edited=”on|phone” text_font_size_tablet=”” text_font_size_phone=”13px” text_font_size_last_edited=”on|phone” text_line_height_tablet=”” text_line_height_phone=”1.4em” text_line_height_last_edited=”on|phone” global_colors_info=”{}”]<\/p>\n

R3i\u793e\u8aac\u306f\u3001R3i\u7406\u4e8b\u4f1a\u306e\u30e1\u30f3\u30d0\u30fc\u306b\u3088\u3063\u3066\u4f5c\u6210\u3055\u308c\u3001\u5fc3\u8840\u7ba1\u30ea\u30b9\u30af\u306e\u6b8b\u5b58\u3068\u3044\u3046\u6c38\u7d9a\u7684\u306a\u8ab2\u984c\u3078\u306e\u5bfe\u51e6\u306b\u7126\u70b9\u3092\u5f53\u3066\u3066\u3044\u308b\u3002\u3053\u308c\u3089\u306e\u8ad6\u8aac\u306f\u3001\u30c8\u30ea\u30b0\u30ea\u30bb\u30ea\u30c9\u30ea\u30c3\u30c1\u30ea\u30dd\u86cb\u767d\u3084\u30ea\u30dd\u86cb\u767d(a)\u306a\u3069\u306e\u8102\u8cea\u95a2\u9023\u5371\u967a\u56e0\u5b50\u306b\u95a2\u3059\u308b\u65b0\u305f\u306a\u77e5\u898b\u3084\u6cbb\u7642\u6226\u7565\u306b\u3064\u3044\u3066\u3001\u533b\u7642\u5c02\u9580\u5bb6\u3092\u6559\u80b2\u3059\u308b\u5f79\u5272\u3092\u679c\u305f\u3057\u3066\u3044\u308b\u3002 <\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.27.3″ _module_preset=”default” custom_margin=”-49px|||||” custom_padding=”2px||40px|||” global_colors_info=”{}”][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.27.4″ _module_preset=”default” border_radii=”off|13px|13px|13px|13px” border_width_all=”4px” border_color_all=”gcid-b673dc17-1b2a-464e-affa-1bf1ab41c0fd” border_width_all_tablet=”4px” border_width_all_phone=”0px” border_width_all_last_edited=”on|phone” border_color_all_tablet=”gcid-b673dc17-1b2a-464e-affa-1bf1ab41c0fd” border_color_all_phone=”gcid-b673dc17-1b2a-464e-affa-1bf1ab41c0fd” border_color_all_last_edited=”on|phone” box_shadow_style=”preset2″ global_colors_info=”{%22gcid-b673dc17-1b2a-464e-affa-1bf1ab41c0fd%22:%91%22border_color_all%22%93}”][et_pb_column type=”1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font_size=”14px” header_5_text_color=”gcid-4907c8d4-9eff-49de-91ce-43a2d3a729cf” header_6_text_color=”gcid-secondary-color” hover_enabled=”0″ inline_fonts=”Abyssinica SIL” global_colors_info=”{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-4907c8d4-9eff-49de-91ce-43a2d3a729cf%22:%91%22header_5_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}” sticky_enabled=”0″]<\/p>\n

October 2025<\/span><\/h5>\n
\u30ea\u30dd\u30bf\u30f3\u30d1\u30af\u8cea(a)\u306f\u6b8b\u5b58\u5fc3\u8840\u7ba1\u30ea\u30b9\u30af\u56e0\u5b50\u3067\u3042\u308b\uff1a\u7279\u5b9a\u3068\u7ba1\u7406<\/h5>\n
Prof. Peter Libby<\/a>, <\/span>Prof. Michel Hermans<\/a>, Prof. Pierre Amarenco<\/a>, Prof. Lale Tokg\u00f6zoglu <\/a><\/span> <\/h6>\n

\u30ea\u30dd\u30bf\u30f3\u30d1\u30af(a)\u3014Lp(a)\u3015\u3092\u6b8b\u5b58\u5fc3\u8840\u7ba1\u30ea\u30b9\u30af\u56e0\u5b50\u3068\u3057\u3066\u6349\u3048\u308b\u6a5f\u904b\u304c\u9ad8\u307e\u3063\u3066\u3044\u308b\u3002\u9ad8Lp(a)\u304c\u30a2\u30c6\u30ed\u30fc\u30e0\u52d5\u8108\u786c\u5316\u6027\u5fc3\u8840\u7ba1\u75be\u60a3\uff08ASCVD\uff09\u30ea\u30b9\u30af\u3092\u5897\u52a0\u3055\u305b\u308b\u3068\u3044\u3046\u56e0\u679c\u95a2\u4fc2\u3092\u652f\u6301\u3059\u308b\u30a8\u30d3\u30c7\u30f3\u30b9\u306f\u3059\u3067\u306b\u660e\u78ba\u3067\u3042\u308b(1)\u3002\u3053\u306e\u77e5\u898b\u306b\u57fa\u3065\u304d\u3001\u5404\u7a2e\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u306f\u6210\u4eba\u3067\u5c11\u306a\u304f\u3068\u30821\u56de\u306eLp(a)\u6e2c\u5b9a\u3092\u63a8\u5968\u3057\u3001\u9ad8Lp(a)\u3092\u30ea\u30b9\u30af\u5897\u5f37\u56e0\u5b50\u3068\u3057\u3066\u4f4d\u7f6e\u3065\u3051\u3001\u7279\u7570\u7684\u6cbb\u7642\u304c\u672a\u627f\u8a8d\u3067\u3042\u308b\u73fe\u6642\u70b9\u3067\u306f\u53ef\u5909\u7684\u5371\u967a\u56e0\u5b50\u306e\u53b3\u683c\u7ba1\u7406\u3092\u52e7\u544a\u3057\u3066\u3044\u308b(2\u20135)\u3002\u9ad8Lp(a)\u306e\u95be\u5024\u306b\u666e\u904d\u7684\u5408\u610f\u306f\u306a\u3044\u3082\u306e\u306e\u3001**\u96c6\u56e380\u30d1\u30fc\u30bb\u30f3\u30bf\u30a4\u30eb\u8d85\uff08>50 mg\/dL \u307e\u305f\u306f >100\u2013125 nmol\/L\uff09**\u304c\u3001\u30ea\u30b9\u30af\u306b\u5bc4\u4e0e\u3059\u308b\u4e0a\u6607\u3092\u5b9a\u7fa9\u3059\u308b\u5b9f\u52d9\u7684\u306a\u57fa\u6e96\u3068\u3057\u3066\u63d0\u6848\u3055\u308c\u3066\u3044\u308b(1,2)\u3002 <\/p>\n

\u9ad8Lp(a)\u306e\u540c\u5b9a\u306f\u3001\u9ad8\u30ea\u30b9\u30af\u60a3\u8005\u306e\u6cbb\u7642\u6226\u7565\u3092\u8abf\u6574\u3059\u308b\u3046\u3048\u3067\u91cd\u8981\u306a\u4e88\u5f8c\u60c5\u5831\u3092\u4e0e\u3048\u308b\u3002\u6025\u6027\u51a0\u75c7\u5019\u7fa4\uff08ACS\uff09\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305fODYSSEY OUTCOMES\u3067\u306f\u3001\u9ad8Lp(a)\u306e\u53c2\u52a0\u8005\u3067PCSK9\u963b\u5bb3\u85ac\u30a2\u30ea\u30ed\u30af\u30de\u30d6\u306e\u4fbf\u76ca\u304c\u3088\u308a\u5927\u304d\u304f\u3001\u4f4eLp(a)\u7fa4\u306b\u6bd4\u3079\u5fc3\u8840\u7ba1\u30a4\u30d9\u30f3\u30c8\u304a\u3088\u3073\u4e0b\u80a2\u6709\u5bb3\u4e8b\u8c61\u306e\u4f4e\u6e1b\u304c\u9855\u8457\u3067\u3042\u3063\u305f(6,7)\u3002\u672c\u53f7\u306e\u30e9\u30f3\u30c9\u30de\u30fc\u30af\u3067\u53d6\u308a\u4e0a\u3052\u308btime-to-event\u89e3\u6790\u3067\u306f\u3001\u3053\u306e\u4fbf\u76ca\u304c\u5fc3\u8840\u7ba1\u30a4\u30d9\u30f3\u30c8\u306715\u304b\u6708\u304b\u3089\u3001\u4e0b\u80a2\u6709\u5bb3\u4e8b\u8c61\u3067\u306f\u958b\u59cb\u5f8c3\u304b\u6708\u672a\u6e80\u3068\u3044\u3046\u65e9\u671f\u304b\u3089\u660e<\/a>\u77ad\u3067\u3042\u308b\u3053\u3068\u304c\u793a\u3055\u308c\u305f(8)\u3002 <\/p>\n

\u3055\u3089\u306b\u3001\u672c\u53f7\u306e\u30d5\u30a9\u30fc\u30ab\u30b9\u30ec\u30dd\u30fc\u30c8\u306f\u3001\u672b\u68a2\u52d5\u8108\u75be\u60a3\uff08PAD\uff09\u306b\u304a\u3051\u308b\u9ad8Lp(a)<\/a>\u306e\u4e88\u5f8c\u7684\u610f\u7fa9\u3092\u793a\u3059\u3002Mass General Brigham\u306eLp(a)\u30ec\u30b8\u30b9\u30c8\u30ea\uff08PAD\u7d044,000\u4f8b\uff09\u306e\u5b9f\u81e8\u5e8a\u30c7\u30fc\u30bf\u3067\u306f\u3001\u9ad8Lp(a)\u304c\u5fc3\u8840\u7ba1\u30a4\u30d9\u30f3\u30c8\u3068\u4e0b\u80a2\u30a4\u30d9\u30f3\u30c8\u53cc\u65b9\u306e\u30ea\u30b9\u30af\u5897\u52a0\u3068\u95a2\u9023\u3057\u305f\u3002\u3068\u304f\u306b42\u301c<132 nmol\/L\uff08\u4e0a\u9650\u306f\u6982\u306d50 mg\/dL\u306b\u76f8\u5f53(1)\uff09\u306e\u60a3\u8005\u3067MACE\u30ea\u30b9\u30af\u304c24%\u5897\u52a0\uff08p=0.005\uff09\u3057\u3001\u6700\u4e0a\u4f4d\u56db\u5206\u4f4d\u3067\u306f30%\u306b\u9054\u3057\u305f\u3002\u4e0b\u80a2\u30a4\u30d9\u30f3\u30c8\u306b\u3064\u3044\u3066\u3082Lp(a)\u6700\u4e0a\u4f4d\u7fa4\u3067\u30ea\u30b9\u30af\u5897\u52a0\u3092\u8a8d\u3081\u3001\u7b2c3\u56db\u5206\u4f4d\u3067\u6709\u610f\u5dee\u304c\u5f97\u3089\u308c\u306a\u304b\u3063\u305f\u306e\u306f\u30a4\u30d9\u30f3\u30c8\u6570\u306e\u4e0d\u8db3\u304c\u5f71\u97ff\u3057\u305f\u53ef\u80fd\u6027\u304c\u3042\u308b\u3002 <\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_text_color=”gcid-4907c8d4-9eff-49de-91ce-43a2d3a729cf” text_font_size=”14px” hover_enabled=”0″ global_colors_info=”{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-4907c8d4-9eff-49de-91ce-43a2d3a729cf%22:%91%22text_text_color%22%93}” sticky_enabled=”0″]<\/p>\n

\u5404\u7814\u7a76\u306b\u9650\u754c\u306f\u3042\u308b\u304c\u3001\u9ad8Lp(a)\u3092\u4f34\u3046\u9ad8\u30ea\u30b9\u30af\u60a3\u8005\u3067\u306f\u3001\u5fc3\u8840\u7ba1\u30fb\u4e0b\u80a2\u6709\u5bb3\u4e8b\u8c61\u306e\u53cc\u65b9\u306e\u30ea\u30b9\u30af\u304c\u5897\u52a0\u3059\u308b\u3068\u3044\u3046\u30e1\u30c3\u30bb\u30fc\u30b8\u306f\u63fa\u308b\u304c\u306a\u3044\u3002PAD\u306f\u6709\u75c5\u7387\u304c\u9ad8\u3044\u306b\u3082\u304b\u304b\u308f\u3089\u305a\u904e\u5c11\u8a3a\u65ad\u30fb\u904e\u5c11\u6cbb\u7642\u304c\u7d9a\u3044\u3066\u304a\u308a(10,11)\u3001\u305d\u306e\u5f71\u97ff\u306f\u5927\u304d\u3044\u3002\u4e0b\u80a2PAD\u306fASCVD\u95a2\u9023\u7f79\u60a3\u306e\u4e3b\u8981\u56e0\u306e\u4e00\u3064\uff08\u7b2c3\u4f4d\uff09\u3067\u3042\u308a(12)\u3001\u4eba\u53e3\u9ad8\u9f62\u5316\u306b\u4f34\u3044\u5fc3\u8840\u7ba1\u75be\u60a3\u3068\u91cd\u75c7\u4e0b\u80a2\u865a\u8840\u306e\u5408\u4f75\u75c7\u7ba1\u7406\u30b3\u30b9\u30c8\u306e\u305f\u3081\u4e16\u754c\u7684\u533b\u7642\u8ca0\u62c5\u306f\u3055\u3089\u306b\u5897\u5927\u3059\u308b\u3068\u898b\u8fbc\u307e\u308c\u308b(12,13,14)\u3002 <\/p>\n

\u9ad8Lp(a)\u304c\u5927\u52d5\u8108\u9818\u57df\u3092\u542b\u3080PAD\u306e\u9032\u884c\u3068\u95a2\u9023\u3057(12)\u3001\u5fc3\u8840\u7ba1\u304a\u3088\u3073\u4e0b\u80a2\u306e\u6709\u5bb3\u4e8b\u8c61\u30ea\u30b9\u30af\u3092\u9ad8\u3081\u308b\u3068\u3044\u3046\u30a8\u30d3\u30c7\u30f3\u30b9\u306f\u5f37\u3044\u3002\u3053\u308c\u3089\u306e\u77e5\u898b\u306f\u3001\u6700\u3082\u30ea\u30b9\u30af\u304c\u9ad8\u3044\u60a3\u8005\u3092\u898b\u6975\u3081\u6700\u9069\u6cbb\u7642\u3092\u8abf\u6574\u3059\u308b\u305f\u3081\u306bLp(a)\u3092\u6e2c\u5b9a\u3059\u308b\u3053\u3068\u306e\u6c7a\u5b9a\u7684\u306a\u91cd\u8981\u6027\u3092\u518d\u78ba\u8a8d\u3055\u305b\u308b(3)\u3002\u3053\u306e\u6226\u7565\u306e\u5b9f\u88c5\u306b\u306f\u3001Lp(a)\u6e2c\u5b9a\u306b\u95a2\u3059\u308b\u81e8\u5e8a\u73fe\u5834\u306e\u60f0\u6027\uff08clinical inertia\uff09\u306e\u514b\u670d\u304c\u9375\u3067\u3042\u308b\u3002\u9ad8Lp(a)\u3092\u4f34\u3046\u9ad8\u30ea\u30b9\u30af\u60a3\u8005\u306e\u6b8b\u5b58\u8840\u7ba1\u30ea\u30b9\u30af\u3092\u4f4e\u6e1b\u3059\u308b\u3053\u3068\u306f\u3001\u751f\u6d3b\u306e\u8cea\u3068\u7f79\u60a3\u306e\u6539\u5584\u306b\u8cc7\u3059\u308b\u3060\u3051\u3067\u306a\u304f\u3001\u903c\u8feb\u3059\u308b\u533b\u7642\u8cc7\u6e90\u4e0b\u3067\u533b\u7642\u4f53\u5236\u306b\u3082\u76ca\u3092\u3082\u305f\u3089\u3059\u3002\u52a0\u3048\u3066\u3001Lp(a)\u306f\u907a\u4f1d\u6027\u304c\u5f37\u3044\u305f\u3081\u3001\u6e2c\u5b9a\u306f\u5bb6\u65cf\u5185\u30ab\u30b9\u30b1\u30fc\u30c9\u30b9\u30af\u30ea\u30fc\u30cb\u30f3\u30b0\u306e\u5951\u6a5f\u3068\u3082\u306a\u308a\u5f97\u308b\u3002 <\/p>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font_size=”8px” global_colors_info=”{}”]<\/p>\n

\u53c2\u8003\u6587\u732e<\/b><\/p>\n

    \n
  1. 1. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 2022;43:3925\u201346.
    2. Wilson DP, Jacobson TA, Jones PH, et al. Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol 2019;13:374\u201392.
    3. Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol 2021;37:1129\u201350.
    4. Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis 2019;290:140\u2013205.
    5. Mach F, Koskinas KC, Roeters van Lennep JE, et al. Focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias. Atherosclerosis 2025.     https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120479<\/a>.
    6. Szarek M, Bittner VA, Aylward P et al. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. Eur Heart J 2020;41:4245-55.
    7. Schwartz GG, Steg PG, Szarek M et al. Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: role of lipoprotein(a) and modification by alirocumab: prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial. Circulation 2020;141:1608-17.
    8. Ray KK, Szarek M, Bhatt DL, et al. Lipoprotein(a) identifies patients with acute coronary syndromes who derive cardiovascular benefit from alirocumab, particularly for limb events. J Am Coll Cardiol 2025;     https:\/\/doi.org\/10.1016\/j.jacc.2025.08.043<\/a>
    9. McClintick DJ, Biery DW, Berman AN, et al. Association between lipoprotein(a) and cardiovascular events in patients with peripheral artery disease: the Mass General Brigham Lp(a) registry. Eur J Prevent Cardiol 2025;     https:\/\/doi.org\/10.1093\/eurjpc\/zwaf475<\/a>
    10. Varvel S, McConnell JP, Tsimikas S. Prevalence of elevated Lp(a) mass levels and patient
    thresholds in 532 359 patients in the United States. Arterioscler Thromb Vasc Biol 2016;36:2239\u201345.
    11. Criqui MH, Matsushita K, Aboyans V, et al. Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American Heart Association. Circulation 2021;144:e171\u2013e191.
    12. Global Burden of Disease study. Global burden of peripheral artery disease and its risk factors. 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet Global Health 2023;11:e1553\u2013e1565.
    13. Prince MJ, Wu F, Guo Y, et al. The burden of disease in older people and implications for health policy and practice. Lancet 2015; 385:549\u201362.
    14. Aboyans V, Criqui MH, Denenberg JO, et al. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation 2006;113:2623\u20139. <\/li>\n<\/ol>\n

    Key words: Lipoprotein(a); peripheral artery disease; ODYSSEY OUTCOMES; residual vascular risk<\/em><\/p>\n

      \n
    1. \n<\/li>\n<\/ol>\n

      [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

      R3i\u793e\u8aacR3i\u793e\u8aac\u306f\u3001R3i\u7406\u4e8b\u4f1a\u306e\u30e1\u30f3\u30d0\u30fc\u306b\u3088\u3063\u3066\u4f5c\u6210\u3055\u308c\u3001\u5fc3\u8840\u7ba1\u30ea\u30b9\u30af\u306e\u6b8b\u5b58\u3068\u3044\u3046\u6c38\u7d9a\u7684\u306a\u8ab2\u984c\u3078\u306e\u5bfe\u51e6\u306b […]<\/p>\n","protected":false},"author":258497325,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_crdt_document":"","jetpack_post_was_ever_published":false,"footnotes":""},"class_list":["post-257161","page","type-page","status-publish","hentry"],"yoast_head":"\nLipoprotein(a): Identify and Manage Residual Risk - R3i<\/title>\n<meta name=\"description\" content=\"High Lp(a) levels increase risk for ASCVD and limb events. Learn from Prof. Peter Libby about Lp(a) screening, management strategies, and findings from the ODYSSEY OUTCOMES trial on residual risk reduction.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/r3i.org\/ja\/editorials-10-25-%e3%83%aa%e3%83%9d%e3%82%bf%e3%83%b3%e3%83%91%e3%82%afa%e3%81%af%e6%ae%8b%e5%ad%98%e5%bf%83%e8%a1%80%e7%ae%a1%e3%83%aa%e3%82%b9%e3%82%af%e5%9b%a0%e5%ad%90%ef%bc%9a%e5%90%8c\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lipoprotein(a): Identify and Manage Residual Risk - R3i\" \/>\n<meta property=\"og:description\" content=\"High Lp(a) levels increase risk for ASCVD and limb events. Learn from Prof. Peter Libby about Lp(a) screening, management strategies, and findings from the ODYSSEY OUTCOMES trial on residual risk reduction.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/r3i.org\/ja\/editorials-10-25-%e3%83%aa%e3%83%9d%e3%82%bf%e3%83%b3%e3%83%91%e3%82%afa%e3%81%af%e6%ae%8b%e5%ad%98%e5%bf%83%e8%a1%80%e7%ae%a1%e3%83%aa%e3%82%b9%e3%82%af%e5%9b%a0%e5%ad%90%ef%bc%9a%e5%90%8c\/\" \/>\n<meta property=\"og:site_name\" content=\"R3I\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-05T16:56:19+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data1\" content=\"5\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/r3i.org\\\/ja\\\/editorials-10-25-%e3%83%aa%e3%83%9d%e3%82%bf%e3%83%b3%e3%83%91%e3%82%afa%e3%81%af%e6%ae%8b%e5%ad%98%e5%bf%83%e8%a1%80%e7%ae%a1%e3%83%aa%e3%82%b9%e3%82%af%e5%9b%a0%e5%ad%90%ef%bc%9a%e5%90%8c\\\/\",\"url\":\"https:\\\/\\\/r3i.org\\\/ja\\\/editorials-10-25-%e3%83%aa%e3%83%9d%e3%82%bf%e3%83%b3%e3%83%91%e3%82%afa%e3%81%af%e6%ae%8b%e5%ad%98%e5%bf%83%e8%a1%80%e7%ae%a1%e3%83%aa%e3%82%b9%e3%82%af%e5%9b%a0%e5%ad%90%ef%bc%9a%e5%90%8c\\\/\",\"name\":\"Lipoprotein(a): Identify and Manage Residual Risk - R3i\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/r3i.org\\\/ja\\\/#website\"},\"datePublished\":\"2025-12-13T17:38:36+00:00\",\"dateModified\":\"2026-03-05T16:56:19+00:00\",\"description\":\"High Lp(a) levels increase risk for ASCVD and limb events. Learn from Prof. Peter Libby about Lp(a) screening, management strategies, and findings from the ODYSSEY OUTCOMES trial on residual risk reduction.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/r3i.org\\\/ja\\\/editorials-10-25-%e3%83%aa%e3%83%9d%e3%82%bf%e3%83%b3%e3%83%91%e3%82%afa%e3%81%af%e6%ae%8b%e5%ad%98%e5%bf%83%e8%a1%80%e7%ae%a1%e3%83%aa%e3%82%b9%e3%82%af%e5%9b%a0%e5%ad%90%ef%bc%9a%e5%90%8c\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/r3i.org\\\/ja\\\/editorials-10-25-%e3%83%aa%e3%83%9d%e3%82%bf%e3%83%b3%e3%83%91%e3%82%afa%e3%81%af%e6%ae%8b%e5%ad%98%e5%bf%83%e8%a1%80%e7%ae%a1%e3%83%aa%e3%82%b9%e3%82%af%e5%9b%a0%e5%ad%90%ef%bc%9a%e5%90%8c\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/r3i.org\\\/ja\\\/editorials-10-25-%e3%83%aa%e3%83%9d%e3%82%bf%e3%83%b3%e3%83%91%e3%82%afa%e3%81%af%e6%ae%8b%e5%ad%98%e5%bf%83%e8%a1%80%e7%ae%a1%e3%83%aa%e3%82%b9%e3%82%af%e5%9b%a0%e5%ad%90%ef%bc%9a%e5%90%8c\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/r3i.org\\\/ja\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Editorials 10\\\/25 – \u30ea\u30dd\u30bf\u30f3\u30d1\u30af(a)\u306f\u6b8b\u5b58\u5fc3\u8840\u7ba1\u30ea\u30b9\u30af\u56e0\u5b50\uff1a\u540c\u5b9a\u3068\u7ba1\u7406\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/r3i.org\\\/ja\\\/#website\",\"url\":\"https:\\\/\\\/r3i.org\\\/ja\\\/\",\"name\":\"R3I\",\"description\":\"Residual Risk Reduction Initiative\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/r3i.org\\\/ja\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lipoprotein(a): Identify and Manage Residual Risk - R3i","description":"High Lp(a) levels increase risk for ASCVD and limb events. Learn from Prof. Peter Libby about Lp(a) screening, management strategies, and findings from the ODYSSEY OUTCOMES trial on residual risk reduction.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/r3i.org\/ja\/editorials-10-25-%e3%83%aa%e3%83%9d%e3%82%bf%e3%83%b3%e3%83%91%e3%82%afa%e3%81%af%e6%ae%8b%e5%ad%98%e5%bf%83%e8%a1%80%e7%ae%a1%e3%83%aa%e3%82%b9%e3%82%af%e5%9b%a0%e5%ad%90%ef%bc%9a%e5%90%8c\/","og_locale":"ja_JP","og_type":"article","og_title":"Lipoprotein(a): Identify and Manage Residual Risk - R3i","og_description":"High Lp(a) levels increase risk for ASCVD and limb events. Learn from Prof. Peter Libby about Lp(a) screening, management strategies, and findings from the ODYSSEY OUTCOMES trial on residual risk reduction.","og_url":"https:\/\/r3i.org\/ja\/editorials-10-25-%e3%83%aa%e3%83%9d%e3%82%bf%e3%83%b3%e3%83%91%e3%82%afa%e3%81%af%e6%ae%8b%e5%ad%98%e5%bf%83%e8%a1%80%e7%ae%a1%e3%83%aa%e3%82%b9%e3%82%af%e5%9b%a0%e5%ad%90%ef%bc%9a%e5%90%8c\/","og_site_name":"R3I","article_modified_time":"2026-03-05T16:56:19+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"5\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/r3i.org\/ja\/editorials-10-25-%e3%83%aa%e3%83%9d%e3%82%bf%e3%83%b3%e3%83%91%e3%82%afa%e3%81%af%e6%ae%8b%e5%ad%98%e5%bf%83%e8%a1%80%e7%ae%a1%e3%83%aa%e3%82%b9%e3%82%af%e5%9b%a0%e5%ad%90%ef%bc%9a%e5%90%8c\/","url":"https:\/\/r3i.org\/ja\/editorials-10-25-%e3%83%aa%e3%83%9d%e3%82%bf%e3%83%b3%e3%83%91%e3%82%afa%e3%81%af%e6%ae%8b%e5%ad%98%e5%bf%83%e8%a1%80%e7%ae%a1%e3%83%aa%e3%82%b9%e3%82%af%e5%9b%a0%e5%ad%90%ef%bc%9a%e5%90%8c\/","name":"Lipoprotein(a): Identify and Manage Residual Risk - R3i","isPartOf":{"@id":"https:\/\/r3i.org\/ja\/#website"},"datePublished":"2025-12-13T17:38:36+00:00","dateModified":"2026-03-05T16:56:19+00:00","description":"High Lp(a) levels increase risk for ASCVD and limb events. Learn from Prof. Peter Libby about Lp(a) screening, management strategies, and findings from the ODYSSEY OUTCOMES trial on residual risk reduction.","breadcrumb":{"@id":"https:\/\/r3i.org\/ja\/editorials-10-25-%e3%83%aa%e3%83%9d%e3%82%bf%e3%83%b3%e3%83%91%e3%82%afa%e3%81%af%e6%ae%8b%e5%ad%98%e5%bf%83%e8%a1%80%e7%ae%a1%e3%83%aa%e3%82%b9%e3%82%af%e5%9b%a0%e5%ad%90%ef%bc%9a%e5%90%8c\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/r3i.org\/ja\/editorials-10-25-%e3%83%aa%e3%83%9d%e3%82%bf%e3%83%b3%e3%83%91%e3%82%afa%e3%81%af%e6%ae%8b%e5%ad%98%e5%bf%83%e8%a1%80%e7%ae%a1%e3%83%aa%e3%82%b9%e3%82%af%e5%9b%a0%e5%ad%90%ef%bc%9a%e5%90%8c\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/r3i.org\/ja\/editorials-10-25-%e3%83%aa%e3%83%9d%e3%82%bf%e3%83%b3%e3%83%91%e3%82%afa%e3%81%af%e6%ae%8b%e5%ad%98%e5%bf%83%e8%a1%80%e7%ae%a1%e3%83%aa%e3%82%b9%e3%82%af%e5%9b%a0%e5%ad%90%ef%bc%9a%e5%90%8c\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/r3i.org\/ja\/"},{"@type":"ListItem","position":2,"name":"Editorials 10\/25 – \u30ea\u30dd\u30bf\u30f3\u30d1\u30af(a)\u306f\u6b8b\u5b58\u5fc3\u8840\u7ba1\u30ea\u30b9\u30af\u56e0\u5b50\uff1a\u540c\u5b9a\u3068\u7ba1\u7406"}]},{"@type":"WebSite","@id":"https:\/\/r3i.org\/ja\/#website","url":"https:\/\/r3i.org\/ja\/","name":"R3I","description":"Residual Risk Reduction Initiative","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/r3i.org\/ja\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"}]}},"jetpack_likes_enabled":true,"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/Pgbfv2-14TL","jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/pages\/257161","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/users\/258497325"}],"replies":[{"embeddable":true,"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/comments?post=257161"}],"version-history":[{"count":8,"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/pages\/257161\/revisions"}],"predecessor-version":[{"id":257397,"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/pages\/257161\/revisions\/257397"}],"wp:attachment":[{"href":"https:\/\/r3i.org\/ja\/wp-json\/wp\/v2\/media?parent=257161"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}